The CCR5 Delta 32 DELETION of immune proteins is bad and has always been bad for people fighting any infection needing fully functioning immune cells.
When HIV patients are given immune cell inhibitors to reduce the AID's it also leaves them prone to die from other infections.
Consider that there are so many forms of degraded mutations in modern humans it is very difficult to isolate causes. So, we look at many studies on the same subject to draw conclusions. The CCR5 Delta 32 is a bad mutation that is associated with suffering and death in over 20 diseases that have been studied so far.
Clinical Significance of the CCR5delta32 Allele in Hepatitis CIsabelle Morard mail, Sophie Clément, Alexandra Calmy, Alessandra Mangia, Andrea Cerny, Andrea De Gottardi, Meri Gorgievski, Markus Heim, Raffaele Malinverni, Darius Moradpour, Beat Müllhaupt, David Semela, Stéphanie Pascarella, Pierre-Yves Bochud, Franco Negro,
on behalf of the Swiss Hepatitis C Cohort Study Group
"In conclusion, our results, based on a large cohort of 1,450 HCV-infected patients, genotyped for the CCR5delta32 allele and representative of the distribution of this allele in a Caucasian population, showed that that both IFNL3 rs1297860 CT/TT and CCR5delta32 alleles were associated with a decreased spontaneous HCV clearance, although the multivariate analysis barely failed to reach statistical significance for the latter. The CCR5delta32 deletion was not associated with fibrosis, fibrosis progression rate, or therapy response. In the view that CCR5 inhibitors are now available for HIV treatment, this is an important observation: our data suggest that these drugs could impair the odds of spontaneous clearance of acute HCV infection in HIV-infected patients on active treatment with anti-CCR5. However drug-induced impairment of CCR5 signaling should neither modify HCV histological outcomes nor impair the efficacy of anti-HCV therapy."
You can read more here: